Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 09/13/16 → 09/12/17 |
Funding
- Gilead Sciences Incorporated: $6,625.00
Start Up Fees: Study Evaluating the Efficacy and Safety of Idelalisib in Combination with Obinutuzumab Compared to Chlorambucil in Combination with Obinutuzumab for Previously Untreated Chronic Lymphocytic
- Schuster, Michael (PI)
- Gabig, Theodore (CoPI)
- Lan, Fengshuo (CoPI)
- Kiner-Strachan, Bonnie (CoPI)
Project: Research